Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 6/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 9/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 9/20 | 0.35 |
| ▸ | GCK | P35557 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | CPT2 | P23786 | 1/20 | 0.33 |
| ▸ | CPT1A | P50416 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12661190 | 0.88 | USP30 (0.41) | PRCP | |
| SCHEMBL2454437 | 0.86 | HCRTR1 (0.38) | PRCPHCRTR1HCRTR2CYP3A4CYP2C9 | |
| SCHEMBL27855003 | 0.85 | HCRTR1 (0.39) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL3781488 | 0.85 | HCRTR1 (0.39) | HCRTR1HCRTR2CYP3A4 | |
| SCHEMBL932420 | 0.84 | HCRTR1 (0.39) | HCRTR1HCRTR2GRM5 | |
| SCHEMBL3448741 | 0.82 | TP53 (0.39) | HCRTR1HCRTR2CPT2CPT1A | |
| SCHEMBL16499066 | 0.81 | GRM5 (0.36) | PRCPHCRTR1HCRTR2GRM5CPT2 | |
| SCHEMBL2363127 | 0.81 | HCRTR1 (0.41) | HCRTR1HCRTR2CPT2CPT1A | |
| SCHEMBL18815729 | 0.79 | CPT1A (0.40) | PRCPHCRTR1HCRTR2GRM5CPT2 | |
| SCHEMBL6167855 | 0.78 | CPT1A (0.43) | CPT2CPT1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | PFIZER INC. | 2011-05-12 | — | — | US | disclosed |
| WO-2011004276-A1 | HEPATITIS C VIRUS INHIBITORS | PFIZER LIMITED (GB) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | HAVCR2, SLC10A1, HCCS | PRCP 211/4885HCRTR1 4187/4885HCRTR2 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.